Nafoxadol: Difference between revisions

Nafoxadol
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	82426-48-6
PubChem	65860
DrugBank
ChemSpider	59273
KEGG	D05199

Newer edit →

Revision as of 02:47, 11 December 2024

Nafoxadol is a pharmaceutical compound that has been studied for its potential use as an analgesic, particularly in the management of pain. It belongs to the class of drugs known as piperazine derivatives and has been investigated for its effects on the central nervous system.

Pharmacology

Nafoxadol acts primarily as a serotonin receptor modulator. It has been shown to interact with various subtypes of serotonin receptors, which are involved in the modulation of pain perception. The exact mechanism by which nafoxadol exerts its analgesic effects is not fully understood, but it is believed to involve the modulation of neurotransmitter release in the central nervous system.

Clinical Use

Nafoxadol has been studied in clinical trials for its potential use in treating different types of pain, including neuropathic pain and chronic pain. However, as of the latest updates, it has not been approved for clinical use in any major market. The results of clinical trials have been mixed, with some studies showing promising results while others have not demonstrated significant efficacy compared to placebo.

Side Effects

The side effects of nafoxadol are similar to those of other drugs that modulate serotonin receptors. Common side effects may include nausea, dizziness, and headache. More serious side effects could include serotonin syndrome, especially if used in combination with other serotonergic drugs.

Research and Development

Research into nafoxadol is ongoing, with studies focusing on its pharmacokinetics, pharmacodynamics, and potential therapeutic applications. The development of nafoxadol has been hampered by the complexity of its interactions with multiple serotonin receptor subtypes, which complicates the prediction of its effects in different patient populations.

Also see

References

@@ Line 1: / Line 1: @@
-[[File:Nafoxadol.svg|thumb|Nafoxadol]] '''Nafoxadol''' is a chemical compound that has been studied for its potential pharmacological properties. As of the current knowledge, detailed information about its chemical structure, pharmacodynamics, pharmacokinetics, and clinical applications remains limited. This article aims to provide a comprehensive overview of Nafoxadol, based on the available information.
+{{Drugbox
+| Verifiedfields = changed
+| verifiedrevid = 477241123
+| IUPAC_name = 1-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-4-(2-methoxyphenyl)piperazine
+| image = Nafoxadol.svg
+| width = 200px
+| CAS_number = 82426-48-6
+| ATC_prefix = none
+| PubChem = 65860
+| ChemSpiderID = 59273
+| UNII = 0X9U3V2K4B
+| KEGG = D05199
+| ChEMBL = 2104010
+| C=20
+| H=24
+| N=2
+| O=3
+| smiles = COc1ccccc1N2CCN(CC2)CC3COC4=CC=CC=C4O3
+}}
-==Chemistry==
+'''Nafoxadol''' is a pharmaceutical compound that has been studied for its potential use as an analgesic, particularly in the management of [[pain]]. It belongs to the class of drugs known as [[piperazine]] derivatives and has been investigated for its effects on the central nervous system.
-Nafoxadol belongs to a class of organic compounds known for their complex molecular structures and diverse pharmacological effects. The chemical specifics of Nafoxadol, including its molecular formula, molecular weight, and structural formula, would be crucial in understanding its pharmacological potential and mechanism of action.
-==Pharmacodynamics==
+==Pharmacology==
-The pharmacodynamics of Nafoxadol would involve its mechanism of action, how it interacts with biological systems at the molecular level, and its effects on the body. This could include interactions with receptors, enzymes, or other cellular components, leading to its therapeutic effects or side effects.
+Nafoxadol acts primarily as a [[serotonin receptor]] modulator. It has been shown to interact with various subtypes of serotonin receptors, which are involved in the modulation of pain perception. The exact mechanism by which nafoxadol exerts its analgesic effects is not fully understood, but it is believed to involve the modulation of neurotransmitter release in the central nervous system.
-==Pharmacokinetics==
+==Clinical Use==
-Pharmacokinetics of Nafoxadol would encompass its absorption, distribution, metabolism, and excretion (ADME) profiles. These parameters determine the drug's bioavailability, half-life, and clearance rate from the body, which are essential for optimizing its dosage and understanding its safety profile.
+Nafoxadol has been studied in clinical trials for its potential use in treating different types of pain, including [[neuropathic pain]] and [[chronic pain]]. However, as of the latest updates, it has not been approved for clinical use in any major market. The results of clinical trials have been mixed, with some studies showing promising results while others have not demonstrated significant efficacy compared to placebo.
-==Clinical Applications==
+==Side Effects==
-If Nafoxadol has been investigated for clinical applications, this section would detail the conditions or diseases it aims to treat or manage. It would also include information on clinical trials, efficacy, safety, and potential therapeutic benefits compared to existing treatments.
+The side effects of nafoxadol are similar to those of other drugs that modulate serotonin receptors. Common side effects may include [[nausea]], [[dizziness]], and [[headache]]. More serious side effects could include [[serotonin syndrome]], especially if used in combination with other serotonergic drugs.
-==Safety and Side Effects==
+==Research and Development==
-An overview of the safety profile and side effects associated with Nafoxadol would be critical for assessing its risk-benefit ratio. This includes common and rare side effects, contraindications, and potential drug interactions.
+Research into nafoxadol is ongoing, with studies focusing on its pharmacokinetics, pharmacodynamics, and potential therapeutic applications. The development of nafoxadol has been hampered by the complexity of its interactions with multiple serotonin receptor subtypes, which complicates the prediction of its effects in different patient populations.
-==Current Status==
+==Also see==
-The current status of Nafoxadol research, including any ongoing clinical trials, regulatory approvals, or commercial availability, would provide insight into its potential future applications in medicine.
+* [[Analgesic]]
+* [[Serotonin receptor]]
+* [[Neuropathic pain]]
+* [[Piperazine]]
-[[Category:Chemical compounds]]
+==References==
-[[Category:Pharmacology]]
+{{Reflist}}
-{{stub}}
+[[Category:Analgesics]]
+[[Category:Piperazines]]
+[[Category:Serotonin receptor modulators]]